Lovastatin Induces Multiple Stress Pathways Including LKB1/AMPK Activation That Regulate Its Cytotoxic Effects in Squamous Cell Carcinoma Cells

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Ma, Laurie ^a   Niknejad, Nima ^a   Gorn Hondermann, Ivan ^a   Dayekh, Khalil ^a,b   Dimitroulakos, Jim ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; GEFITINIB; METFORMIN; MEVINOLIN; PROTEIN KINASE LKB1;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CELL STRESS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; EMBRYO; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; METABOLIC STRESS; MITOCHONDRION; NONHUMAN; SQUAMOUS CELL CARCINOMA;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE; CELL LINE, TUMOR; DRUG SYNERGISM; FIBROBLASTS; GENE DELETION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; LOVASTATIN; METFORMIN; MICE; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES; SIGNAL TRANSDUCTION;

EID: 84867021493     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046055     Document Type: Article

References (52)

1. Carnero A, (2010) The PKB/AKT pathway in cancer. Curr Pharm Des 16: 34-44.
2. Lian J, Yan XH, Peng J, Jiang SW, (2008) The mammalian target of rapamycin pathway and its role in molecular nutrition regulation. Mol Nutr Food Res 52: 393-399.
3. Boudeau J, Sapkota G, Alessi DR, (2003) LKB1, a protein kinase regulating cell proliferation and polarity. FEBS Lett 546: 159-165.
4. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, et al. (2003) Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284: 31-53.
5. Wek RC, Jiang HY, Anthony TG, (2006) Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 34: 7-11.
6. Alexander A, Walker CL, (2011) The role of LKB1 and AMPK in cellular responses to stress and damage. FEBS Lett 585: 952-957.
7. Clemens MJ, (2004) Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 23: 3180-3188.
8. Moenner M, Pluquet O, Bouchecareilh M, Chevet E, (2007) Integrated endoplasmic reticulum stress responses in cancer. Cancer Res 67: 10631-10634.
9. Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A, (2001) Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 20: 1594-1600.
10. Mendelsohn J, Baselga J, (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565.
11. Hezel AF, Bardeesy N, (2008) LKB1; linking cell structure and tumor suppression. Oncogene 27: 6908-6919.
12. Buhaescu I, Izzedine H, (2007) Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 40: 575-584.
13. Chan KK, Oza AM, Siu LL, (2003) The statins as anticancer agents. Clin Cancer Res 9: 10-19.
14. Corsini A, Maggi FM, Catapano AL, (1995) Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacological Research 31: 9-27.
15. Goldstein JL, Brown MS, (1990) Regulation of the mevalonate pathway. Nature 343: 425-430.
16. Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, et al. (2001) Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 7: 158-167.
17. Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, et al. (2005) A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer 41: 523-530.
18. Niknejad N, Morley M, Dimitroulakos J, (2007) Activation of the integrated stress response regulates lovastatin-induced apoptosis. J Biol Chem 282: 29748-29756.
19. Zhao TT, Le Francois BG, Goss G, Ding K, Bradbury PA, et al. (2010) Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins. Oncogene 29: 4682-4692.
20. Jiang H-Y, Wek RC, (2005) Phosphorylation of the {alpha}-Subunit of the Eukaryotic Initiation Factor-2 (eIF2{alpha}) Reduces Protein Synthesis and Enhances Apoptosis in Response to Proteasome Inhibition. J Biol Chem 280: 14189-14202.
21. Pawson T, (2002) Regulation and targets of receptor tyrosine kinases. Eur J Cancer 38 (Suppl 5):: S3-10.
22. Holcik M, Sonenberg N, (2005) Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 6: 318-327.
23. Robert F, Pelletier J, (2009) Translation initiation: a critical signalling node in cancer. Expert Opin Ther Targets 13: 1279-1293.
24. Rosner M, Hanneder M, Siegel N, Valli A, Fuchs C, et al. (2008) The mTOR pathway and its role in human genetic diseases. Mutat Res 659: 284-292.
25. Mantha AJ, Hanson JE, Goss G, Lagarde AE, Lorimer IA, et al. (2005) Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin Cancer Res 11: 2398-2407.
26. Viollet B, Mounier R, Leclerc J, Yazigi A, Foretz M, et al. (2007) Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes Metab 33: 395-402.
27. Chiacchiera F, Simone C (2010) The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle 9.
28. Marcus AI, Zhou W, (2010) LKB1 regulated pathways in lung cancer invasion and metastasis. J Thorac Oncol 5: 1883-1886.
29. Makowski L, Hayes DN, (2008) Role of LKB1 in lung cancer development. Br J Cancer 99: 683-688.
30. Dorfman J, Macara IG, (2008) STRADalpha regulates LKB1 localization by blocking access to importin-alpha, and by association with Crm1 and exportin-7. Mol Biol Cell 19: 1614-1626.
31. Kourelis TV, Siegel RD, (2012) Metformin and cancer: new applications for an old drug. Med Oncol 29: 1314-1327.
32. Fu A, Ng AC, Depatie C, Wijesekara N, He Y, et al. (2009) Loss of Lkb1 in adult beta cells increases beta cell mass and enhances glucose tolerance in mice. Cell Metab 10: 285-295.
33. Korade Z, Xu L, Shelton R, Porter NA, (2010) Biological activities of 7-dehydrocholesterol-derived oxysterols: implications for Smith-Lemli-Opitz syndrome. J Lipid Res 51: 3259-3269.
34. Murtola TJ, Syvala H, Pennanen P, Blauer M, Solakivi T, et al. (2012) The Importance of LDL and Cholesterol Metabolism for Prostate Epithelial Cell Growth. PLoS One 7: e39445.
35. Wang AH, Wei L, Chen L, Zhao SQ, Wu WL, et al. (2011) Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells. Ann Hematol 90: 917-931.
36. Daiber A, (2010) Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. Biochim Biophys Acta 1797: 897-906.
37. Huttemann M, Helling S, Sanderson TH, Sinkler C, Samavati L, et al. (2012) Regulation of mitochondrial respiration and apoptosis through cell signaling: cytochrome c oxidase and cytochrome c in ischemia/reperfusion injury and inflammation. Biochim Biophys Acta 1817: 598-609.
38. Sapkota GP, Kieloch A, Lizcano JM, Lain S, Arthur JS, et al. (2001) Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser431 by p90(RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys(433), is essential for LKB1 to suppress cell vrowth. J Biol Chem 276: 19469-19482.
39. DiPaola RS, Dvorzhinski D, Thalasila A, Garikapaty V, Doram D, et al. (2008) Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy. Prostate 68: 1743-1752.
40. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA, (2009) Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS One 4: e6251.
41. Han W, Pan H, Chen Y, Sun J, Wang Y, et al. (2011) EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One 6: e18691.
42. Gibbs JB, Oliff A, Kohl NE, (1994) Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77: 175-178.
43. Sebti S, Hamilton AD, (1997) Inhibitors of prenyl transferases. Curr Opin Oncol 9: 557-561.
44. Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, et al. (2010) Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A 107: 15051-15056.
45. Dimitroulakos J, Yeger H, (1996) HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Nat Med 2: 326-333.
46. Keyomarsi K, Sandoval L, Band V, Pardee AB, (1991) Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51: 3602-3609.
47. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, et al. (1996) Phase 1 study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clinical Cancer Res 2: 483-491.
48. Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, et al. (1999) Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood 93: 1308-1318.
49. Sinthupibulyakit C, Ittarat W, St Clair WH, St Clair DK, (2010) p53 Protects lung cancer cells against metabolic stress. Int J Oncol 37: 1575-1581.
50. Towler MC, Hardie DG, (2007) AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100: 328-341.
51. Herbst RS, (2003) Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol 30: 34-46.
52. Dimitroulakos J, Lorimer IA, Goss G, (2006) Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway. Clin Cancer Res 12: 4426s-4431s.